X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.immutep.com/detail/immutep-reports-positive-results-in-first-line-head-and-neck-squamous-cell-carcinoma-patients-with-negative-pd-l1-expression.html
https://www.globenewswire.com/news-release/2024/07/08/2909486/0/en/iTeos-Announces-First-Patient-Dosed-in-GALAXIES-Lung-301-Phase-3-Study-Earning-35-Million-in-Milestones-from-GSK.html
https://www.prnewswire.com/news-releases/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-agreement-for-kineta-incs-kva12123-novel-anti-vista-checkpoint-inhibitor-302190378.html
https://www.reuters.com/business/healthcare-pharmaceuticals/roche-halt-trial-latest-setback-lung-cancer-immunotherapy-2024-07-04/
https://www.globenewswire.com/news-release/2024/07/03/2908114/0/en/Immutep-Announces-Details-for-Oral-Presentation-at-ESMO-Virtual-Plenary-Session-and-Webcast-to-Discuss-Clinical-Results.html
https://www.prnewswire.com/news-releases/new-efficacy-data-for-non-clear-cell-renal-cell-carcinoma-from-keynote-b61-added-to-lenvima-lenvatinib-us-label-supporting-keytruda--lenvima-indication-for-the-first-line-treatment-of-adult-patients-with-advanced-rcc-302185116.html
https://www.globenewswire.com/news-release/2024/06/26/2904430/0/en/Medicenna-Announces-EMA-Approval-of-its-Clinical-Trial-Application-to-Expand-its-Phase-1-2-ABILITY-1-Study-to-Europe.html
https://www.globenewswire.com/news-release/2024/06/18/2900133/0/en/Precision-Panc-Team-Open-the-PRIMUS-006-Study-a-Novel-Combination-of-IMM-101-Gemcitabine-and-Pembrolizumab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514
https://www.prnewswire.com/news-releases/zumutor-biologics-announces-dosing-of-first-patient-with-zm008-a-first-in-class-anti-llt1-antibody-302170537.html
https://www.globenewswire.com/news-release/2024/06/11/2896458/0/en/Ultimovacs-provides-update-from-Phase-I-study-in-malignant-melanoma-Continued-strong-overall-survival-in-patients-treated-with-UV1-cancer-vaccine-and-pembrolizumab.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514
https://www.globenewswire.com/news-release/2024/06/06/2894893/0/en/CG-Oncology-Announces-Nature-Medicine-Publication-of-Final-Results-from-CORE-001-Study-of-Cretostimogene-Grenadenorepvec-in-Combination-with-Pembrolizumab-in-BCG-Unresponsive-NMIBC.html
https://www.globenewswire.com/news-release/2024/06/04/2893345/0/en/HOOKIPA-Pharma-Announces-Updated-Phase-2-Clinical-Data-at-the-American-Society-of-Clinical-Oncology-2024-Annual-Meeting.html
https://www.fiercepharma.com/pharma/merck-cmo-akeso-summits-keytruda-head-head-win-maybe-another-option-issue
https://www.accesswire.com/870288/moderna-merck-announce-three-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-survival-versus-keytruda-in-patients-with-high-risk-stage
https://www.globenewswire.com/news-release/2024/06/03/2891872/0/en/Immutep-Announces-Clinical-Collaboration-with-MSD-to-Evaluate-Efti-in-Combination-with-KEYTRUDA-pembrolizumab-in-Pivotal-Phase-III-Trial.html
https://www.globenewswire.com/news-release/2024/06/02/2891858/37568/en/Merus-Presents-Interim-Data-on-MCLA-145-Monotherapy-and-in-Combination-with-Pembrolizumab-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/06/01/2891823/0/en/Investigational-Acasunlimab-DuoBody-PD-L1x4-1BB-in-Combination-with-Pembrolizumab-Demonstrates-Meaningful-Clinical-Activity-in-Phase-2-Trial-in-Patients-with-Previously-Treated-Met.html
https://www.prnewswire.com/news-releases/tiumbio-presents-phase-1b-interim-results-for-tu2218-in-combination-with-pembrolizumab-at-asco-2024-annual-meeting-302160236.html
https://www.prnewswire.com/news-releases/updated-data-from-the-phase-12-study-of-olomorasib-in-kras-g12c-mutant-advanced-solid-tumors-presented-at-the-2024-asco-annual-meeting-302160829.html
https://www.globenewswire.com/news-release/2024/06/01/2891818/0/en/Werewolf-Therapeutics-to-Present-Data-from-Ongoing-Phase-1-1b-Clinical-Trial-of-WTX-124-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Solid-Tumors.html
https://www.globenewswire.com/news-release/2024/05/30/2891119/0/en/NextCure-Presents-Phase-1b-Data-on-NC410-and-Pembrolizumab-Combination-at-ASCO-2024.html
https://www.reuters.com/markets/deals/merck-nears-13-bln-cash-deal-eye-drug-company-eyebio-wsj-reports-2024-05-29/
https://www.globenewswire.com/news-release/2024/05/28/2888880/37568/en/Merus-Petosemtamab-in-Combination-with-Pembrolizumab-Interim-Data-Demonstrates-Robust-Response-Rate-and-Favorable-Safety-Profile-in-1L-r-m-HNSCC.html
https://www.healio.com/news/hematology-oncology/20240528/keytruda-extends-survival-in-highrisk-triple-negative-breast-cancer
https://www.pharmaceutical-technology.com/news/asco-2024-rakutens-photoimmunotherapy-and-keytruda-combo-shows-efficacy-in-hnscc/
https://www.fiercepharma.com/pharma/asco-bristol-myers-i-o-triplet-iovance-touts-paradigm-changing-amtagvi-keytruda-melanoma
https://www.globenewswire.com/news-release/2024/05/24/2887943/0/en/CG-Oncology-to-Present-Positive-Final-Results-from-Phase-2-CORE-001-Study-of-Cretostimogene-Grenadenorepvec-in-Combination-with-Pembrolizumab-in-BCG-Unresponsive-High-Risk-NMIBC-at.html
https://www.globenewswire.com/news-release/2024/05/23/2887705/0/en/Cullinan-Therapeutics-to-Present-First-Data-for-CLN-619-a-Novel-Anti-MICA-B-Antibody-in-Combination-with-a-Checkpoint-Inhibitor-and-Updated-Monotherapy-Data-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/05/23/2887693/0/en/HOOKIPA-Pharma-Announces-Positive-Clinical-Data-to-be-Presented-at-the-American-Society-for-Clinical-Oncology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/23/2887681/0/en/Iovance-Biotherapeutics-Announces-Clinical-Data-in-Frontline-Advanced-Melanoma-at-ASCO-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/23/2887679/37568/en/Merus-Announces-Publication-of-Abstracts-for-Presentation-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/23/2887678/37568/en/Merus-Announces-Publication-of-an-Abstract-on-Petosemtamab-with-Pembrolizumab-as-1L-treatment-of-r-m-HNSCC-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/23/2887675/0/en/Werewolf-Therapeutics-to-Present-Updated-Data-from-Phase-1-1b-Clinical-Trial-of-WTX-124-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Solid-Tumors-at-2024-ASCO-Annual-Mee.html
https://www.prnewswire.com/news-releases/dragonfly-therapeutics-inc-announces-clinical-collaboration-to-evaluate-df9001-an-egfr-targeting-trinket-in-combination-with-keytruda-pembrolizumab-in-patients-with-solid-tumors-302150767.html
https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/dragonfly-merck-partner-to-evaluate-df9001-in-combination-with-keytruda/?widget=listSection
https://www.fiercepharma.com/marketing/merck-takes-slim-lead-oncologists-perceptions-amid-fiercely-competitive-environment
https://www.globenewswire.com/news-release/2024/05/15/2882359/37149/en/PDS-Biotech-Provides-Business-Update-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-stops-skin-cancer-combination-therapy-testing-late-stage-study-2024-05-13/
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-treatment-type-uterus-cancer-fails-trial-2024-05-09/
https://www.fiercepharma.com/pharma/mercks-keytruda-plus-chemo-comes-short-post-surgery-therapy-newly-diagnosed-endometrial
https://www.globenewswire.com/news-release/2024/05/09/2878623/0/en/HOOKIPA-Pharma-Reports-First-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html
Market Place
Share 
